Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02710669 · ClinicalTrials.gov registry record · Phase 1
New Formulations of Propafenone to Treat Atrial Fibrillation
A Phase 1 study, sponsored by Vanderbilt University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 193
- Enrollment target
NCT02710669: Clinical Trial Phase 1 study, sponsored by Vanderbilt University.
NCT02710669 is a Phase 1 study that was terminated before completion, run by Vanderbilt University. The registered enrollment target is 193 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (222% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02710669, a Phase 1 study, was terminated before completion, sponsored by Vanderbilt University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 193 participants
- Enrollment target
Study Summary
Propafenone is a currently used medicine to treat atrial fibrillation and is a mixture of two compounds, (R)-propafenone and (S)-propafenone. In this study, the investigators will randomize participants to (R)-propafenone, (S)-propafenone, or placebo.
Primary Outcome
A rapid atrial pacing protocol was used to attempt to induce atrial fibrillation/atrial flutter. Twenty minutes after start of the study drug, participants underwent placement of a decapolar coronary sinus catheter. Pacing was performed from the proximal electrode at 20 milliamps and a pulse width of 2 ms. Bursts from the CS proximal electrode were induced to attempt atrial fibrillation.
Interventions
- DRUG Placebo
- DRUG (R)-propafenone
- DRUG (S)-Propafenone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 193 participants |
| Start Date | 2016-10 |
| Est. Completion | 2020-04 |
| Phase | Phase 1 |
Why NCT02710669 stopped before completion
NCT02710669 is an interventional study that assigns participants to a tested intervention. The registered 193 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (222% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02710669 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02710669 about?
NCT02710669 is a clinical study titled "New Formulations of Propafenone to Treat Atrial Fibrillation". Propafenone is a currently used medicine to treat atrial fibrillation and is a mixture of two compounds, (R)-propafenone and (S)-propafenone. In this study, the investigators will randomize participants to (R)-propafenone, (S)-propafenone, or placebo.
What is the current status of trial NCT02710669?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 193 participants. The study started on 2016-10. Estimated completion is 2020-04.
What interventions are being tested in trial NCT02710669?
The interventions under investigation include: Placebo (DRUG), (R)-propafenone (DRUG), (S)-Propafenone (DRUG).
Who is sponsoring clinical trial NCT02710669?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02710669's enrollment target sits among peer trials
193 282nd of 2000 higher than 1,719 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06226220 · 193 participants · NA
Percutaneous Nerve Evaluation Trial Time
- NCT03593759 · 194 participants · Phase 3
Cardiac Sarcoidosis Randomized Trial
- NCT05053152 · 194 participants · Phase 2
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
- NCT05156112 · 194 participants · NA
OSA PAP Treatment for Veterans With SUD and PTSD on Residential Treatment Unit
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia